Interpretation of treatment results with biological agents: is there a need for a new methodology?

Area of Science:

• Oncology
• Molecular Biology
• Medical Imaging

Background:

• Cancer's biological basis is increasingly understood at the molecular level.
• Traditional assessment of cancer therapy response relies on dimensional changes, which is becoming insufficient.
• Genomic and proteomic analyses are valuable but functional imaging offers a key advancement.

Purpose of the Study:

• To highlight the importance of functional imaging in assessing cancer therapy response.
• To discuss how advanced imaging techniques can improve drug development.
• To emphasize the shift from purely dimensional assessments to functional evaluations of cancer treatment.

Main Methods:

• Utilizing functional analyses of computed tomography (CT) and magnetic resonance imaging (MRI) to understand tumor pathophysiology.
• Employing positron emission tomography (PET) and single photon emission tomography (SPECT) to study drug distribution and therapeutic function.
• Integrating genomic and proteomic data with imaging in preclinical and clinical settings.

Main Results:

• Functional imaging provides critical insights into tumor pathophysiology beyond anatomical changes.
• Advanced imaging techniques allow for the study of drug distribution and efficacy in vivo.
• These methods complement pharmacokinetic and pharmacodynamic assessments.

Conclusions:

• Functional imaging is essential for accurately assessing cancer therapy response.
• Advances in imaging facilitate more effective and safer cancer drug development.
• Integrating molecular understanding with functional imaging will enhance clinical practice.